Gaston Labs is a company.
Gaston Labs has raised $100K across 1 funding round.
Key people at Gaston Labs.
Gaston Labs has raised $100K in total across 1 funding round.
Gaston Medical BV, operating products like Gaston Lab, develops medical monitoring software for clinical chemistry laboratories and hospitals. Gaston Lab analyzes patient medical history alongside lab results, applying protocols to detect dangerous situations and generate automated interpretations, reducing manual consultations for lab professionals.[1][6] It serves hospitals, pharmacists, and clinical labs by preventing medication errors through AI-driven analysis of patient data, lab results, and medications, saving pharmacists up to an hour daily.[6][7]
The software includes modules like the Guideline Module for custom protocols and the Decision Module for integrating with systems such as electronic patient dossiers (EPD), pharmacy systems (AIS), and lab information systems (LIS).[1] This enables faster detection of issues like heparin-induced thrombocytopenia (HIT) than manual clinician review.[1]
Gaston Medical BV, based in the Netherlands, focuses on hospital software to prevent incorrect medication prescriptions.[7] Key figure Dr. Ir. Paul de Clercq, reachable at [email protected], leads development, emphasizing AI integration for patient safety.[1][6] The company evolved from clinical chemistry tools like Gaston Lab to broader AI applications analyzing patient-medication interactions, as highlighted in LIOF testimonials where De Clercq notes smart algorithms' role.[6]
Early traction stems from practical lab needs, such as linking patient age, kidney function, and vitamin data to interpret biomarkers like methylmalonic acid, minimizing manual adjustments.[1] Pivotal growth includes partnerships saving hospital pharmacists significant time, positioning Gaston as a efficiency booster in Dutch healthcare.[6]
Gaston rides the AI in healthcare trend, addressing clinician shortages and error-prone manual processes amid rising patient data complexity.[6] Timing aligns with digital hospital transformations, where integrated systems (EPD/LIS) enable real-time decision support, amplified by post-pandemic demands for efficiency.[1] Market forces like aging populations and medication error regulations favor such tools, reducing risks in clinical chemistry and pharmacy.[7]
Gaston influences the ecosystem by setting standards for AI-monitored labs in Europe, potentially expanding to global hospitals via scalable modules, fostering safer, data-driven care.[1][6]
Gaston Medical positions for growth in AI-healthcare integration, with expansions into more hospital systems and advanced analytics. Trends like predictive diagnostics and regulatory AI mandates will propel modules like Gaston Lab, enhancing its edge in error prevention. Influence may evolve toward multinational adoption, solidifying its role from lab efficiency to comprehensive patient safety platforms—building on its core strength in turning complex data into actionable insights.[1][6][7]
Key people at Gaston Labs.
Gaston Labs has raised $100K in total across 1 funding round.
Gaston Labs's investors include 14W, Archimedes Accelerator LLC, Bling Capital, Brainchild, C2 Investment, Capital Factory, Defy Partners, Founder Collective, Kapor Capital, Long Journey Ventures, Mexican.vc, Precursor Ventures.
Gaston Labs has raised $100K across 1 funding round. Most recently, it raised $100K Seed in February 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2012 | $100K Seed | 14W, Archimedes Accelerator LLC, Bling Capital, Brainchild, C2 Investment, Capital Factory, Defy Partners, Founder Collective, Kapor Capital, Long Journey Ventures, Mexican.vc, Precursor Ventures, SciFi VC, Signal Foundation, SOSV, The Hit Forge, Tiger Global Management, Union Square Ventures, Wasabi Ventures, Y Combinator, Adam Pearsall, Adam Schwartz, Drew Houston, Freada Kapor Klein, Georges Harik, Jacob Kerzner, Joshua Schachter, Kenny Van Zant, Kevin Colas, Lukas Biewald, Roy Rodenstein, Russell Fradin, Russ Fradin, Scott Banister, Ulrich Gall |
